Beneficial Ownership Report · SCHEDULE 13G/A
Yarrow Bioscience, Inc.
YARWNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- YARROW BIOSCIENCE, INC.
- Company CIK
- 0001566044
- Street
- 470 JAMES STREET, SUITE 007
- City
- NEW HAVEN
- State / country code
- CT
- Postal code
- 06513
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.0001
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- Nantahala Capital Management, LLC
- Citizenship / organization
- MA
- Reporting person type
- IA
- Aggregate amount owned
- 39,198.00
- Percent of class
- 0.46
- Sole voting power
- 0.00
- Shared voting power
- 39,198.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 39,198.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Wilmot B. Harkey
- Citizenship / organization
- X1
- Reporting person type
- HC
- Aggregate amount owned
- 39,198.00
- Percent of class
- 0.46
- Sole voting power
- 0.00
- Shared voting power
- 39,198.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 39,198.00
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Daniel Mack
- Citizenship / organization
- X1
- Reporting person type
- HC
- Aggregate amount owned
- 39,198.00
- Percent of class
- 0.46
- Sole voting power
- 0.00
- Shared voting power
- 39,198.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 39,198.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
YARROW BIOSCIENCE, INC.
Principal executive office address
470 JAMES STREET, SUITE 007 NEW HAVEN, CONNECTICUT, 06513
Item 2
Citizenship
(1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
Filing person
(1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
Principal business or residence address
130 Main St. 2nd Floor, New Canaan, Connecticut 06840
Item 3
Not applicable indication
N
Type of filing person
IA · HC
Item 4
Percent of class
As of September 30, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 0.46% (2) Wilmot B. Harkey: 0.46% (3) Daniel Mack: 0.46%
Amount beneficially owned
As of September 30, 2026, Nantahala may be deemed to be the beneficial owner of 39,198 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.
Sole voting power
(1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
Shared voting power
(1) Nantahala Capital Management, LLC ("Nantahala") : 39,198 Shares. (2) Wilmot B. Harkey: 39,198 Shares. (3) Daniel Mack: 39,198 Shares.
Sole dispositive power
(1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
Shared dispositive power
(1) Nantahala Capital Management, LLC ("Nantahala") : 39,198 Shares. (2) Wilmot B. Harkey: 39,198 Shares. (3) Daniel Mack: 39,198 Shares.
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
N
Subsidiaries
Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 24 - Power of Attorney incorporated by reference to the November 13, 2026 filing. https://www.sec.gov/Archives/edgar/data/1502725/000110465926127115/0001104659-26-127115-index.htm.
Signature 1
- Reporting person
- Nantahala Capital Management, LLC
- Signed
- /s/ Taki Vasilakis
- Title
- Taki Vasilakis / Chief Compliance Officer
- Date
- 11/13/2026
Signature 2
- Reporting person
- Wilmot B. Harkey
- Signed
- /s/ Taki Vasilakis, attorney-in-fact for
- Title
- Wilmot B. Harkey
- Date
- 11/13/2026
Signature 3
- Reporting person
- Daniel Mack
- Signed
- /s/ Taki Vasilakis, attorney-in-fact for
- Title
- Daniel Mack
- Date
- 11/13/2026
Company context
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (“TSHR”) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED. For more information, visit www.yarrowbioscience.com.
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Yarrow Bioscience, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Yarrow Bioscience, Inc.Nov 16, 2026
- SCHEDULE 13G - filed by AMERIPRISE FINANCIAL INC regarding Yarrow Bioscience, Inc.Nov 16, 2026
- S-8 filingNov 13, 2026
- 10-Q filingNov 13, 2026